Gilead Sciences Drug Patent Portfolio

Gilead Sciences owns 1 orange book drug protected by 33 US patents Given below is the list of Gilead Sciences's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8598185 Unitary pharmaceutical dosage form 28 Apr, 2029
Active
US9018192 Unitary pharmaceutical dosage form 13 Jun, 2026
Active
US9545414 Unitary pharmaceutical dosage form 13 Jun, 2026
Active
US8716264 Compositions and methods for combination antiviral therapy 03 Jul, 2024 Expired
US8592397 Compositions and methods for combination antiviral therapy 13 Jan, 2024 Expired
US8716264 Compositions and methods for combination antiviral therapy 13 Jan, 2024 Expired
US9457036 Compositions and methods for combination antiviral therapy 13 Jan, 2024 Expired
US9744181 Compositions and methods for combination antiviral therapy 13 Jan, 2024 Expired
US6703396 Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Sep, 2021 Expired
US6642245 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 May, 2021 Expired
US6703396 Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Mar, 2021 Expired
US6642245 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 Nov, 2020 Expired
US6639071 Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 14 Aug, 2018 Expired
US6939964 Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 20 Jul, 2018 Expired
US6639071 Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 14 Feb, 2018 Expired
US5922695 Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability 25 Jan, 2018 Expired
US5935946 Nucleotide analog composition and synthesis method 25 Jan, 2018 Expired
US5977089 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jan, 2018 Expired
US6043230 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jan, 2018 Expired
US6939964 Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 20 Jan, 2018 Expired
US5914331 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 02 Jan, 2018 Expired
US5922695 Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability 25 Jul, 2017 Expired
US5935946 Nucleotide analog composition and synthesis method 25 Jul, 2017 Expired
US5977089 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jul, 2017 Expired
US6043230 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jul, 2017 Expired
US5914331 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 02 Jul, 2017 Expired
US5814639 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds 29 Mar, 2016 Expired
US5814639 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds 29 Sep, 2015 Expired
US5663169 Benzoxazinones as inhibitors of HIV reverse transcriptase 02 Mar, 2015 Expired
US5663169 Benzoxazinones as inhibitors of HIV reverse transcriptase 02 Sep, 2014 Expired
US5519021 Benzoxazinones as inhibitors of HIV reverse transcriptase 21 Nov, 2013 Expired
US5519021 Benzoxazinones as inhibitors of HIV reverse transcriptase 21 May, 2013 Expired
US5811423 Benzoxazinones as inhibitors of HIV reverse transcriptase 07 Aug, 2012 Expired


Given below is the list of recent legal activities going on the following drug patents of Gilead Sciences.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 03 Jul, 2024 US9545414
Payment of Maintenance Fee, 8th Year, Large Entity 12 Oct, 2022 US9018192
Payment of Maintenance Fee, 8th Year, Large Entity 19 May, 2021 US8598185
Payment of Maintenance Fee, 8th Year, Large Entity 12 May, 2021 US8592397
Payment of Maintenance Fee, 4th Year, Large Entity 10 Feb, 2021 US9744181
Payment of Maintenance Fee, 4th Year, Large Entity 02 Jul, 2020 US9545414
Payment of Maintenance Fee, 4th Year, Large Entity 29 Oct, 2018 US9018192
Patent Issue Date Used in PTA Calculation 29 Aug, 2017 US9744181
Recordation of Patent Grant Mailed 29 Aug, 2017 US9744181
Email Notification 10 Aug, 2017 US9744181
Issue Notification Mailed 09 Aug, 2017 US9744181
Application Is Considered Ready for Issue 02 Aug, 2017 US9744181
Dispatch to FDC 02 Aug, 2017 US9744181
Email Notification 01 Aug, 2017 US9744181
Mailing Corrected Notice of Allowability 01 Aug, 2017 US9744181


Gilead Sciences's Drug Patent Litigations

Gilead Sciences's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 05, 2001, against patent number US6642245. The petitioner , challenged the validity of this patent, with DIONNE as the respondent. Click below to track the latest information on how companies are challenging Gilead Sciences's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US5935946 June, 2014 Terminated-Denied
(17 Dec, 2014)
Gilead Sciences, Inc. MYLAN PHARMACEUTICALS INC.
US5922695 June, 2014 Terminated-Denied
(09 Dec, 2014)
Gilead Sciences, Inc. Mylan Pharmaceuticals Inc.
US5977089 June, 2014 Terminated-Denied
(09 Dec, 2014)
Gilead Sciences, Inc. Mylan Pharmaceuticals Inc.
US6043230 June, 2014 Terminated-Denied
(09 Dec, 2014)
Gilead Sciences, Inc. Mylan Pharmaceuticals Inc.
US6703396 April, 2002 Decision
(04 Apr, 2002)
DIONNE
US6642245 July, 2001 Decision
(05 Jul, 2001)
DIONNE


Gilead Sciences Drug Patents' Oppositions Filed in EPO

Gilead Sciences drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 13, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP04701819A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP11167101A Dec, 2015 Hetero Drugs Ltd. Revoked
EP11167101A Dec, 2015 Sandoz AG Revoked
EP11167101A Dec, 2015 Accord Healthcare Ltd Revoked
EP11167101A Dec, 2015 KELTIE LLP Revoked
EP11167101A Dec, 2015 Strawman Limited Revoked
EP06773194A Oct, 2009 Teva Pharmaceutical Industries Ltd. Revoked
EP04701819A Mar, 2009 Generics [UK] Limited Revoked
EP04701819A Mar, 2009 Teva Pharmaceutical Industries LTD. Revoked


Gilead Sciences's Family Patents

Gilead Sciences drugs have patent protection in a total of 31 countries. It's US patent count contributes only to 21.3% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Gilead Sciences Drug List

Given below is the complete list of Gilead Sciences's drugs and the patents protecting them.


1. Atripla

Atripla is protected by 33 patents, out of which 30 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8598185 Unitary pharmaceutical dosage form 28 Apr, 2029
(4 years from now)
Active
US9018192 Unitary pharmaceutical dosage form 13 Jun, 2026
(1 year, 7 months from now)
Active
US9545414 Unitary pharmaceutical dosage form 13 Jun, 2026
(1 year, 7 months from now)
Active
US8716264
(Pediatric)
Compositions and methods for combination antiviral therapy 03 Jul, 2024
(3 months ago)
Expired
US8592397 Compositions and methods for combination antiviral therapy 13 Jan, 2024
(9 months ago)
Expired
US8716264 Compositions and methods for combination antiviral therapy 13 Jan, 2024
(9 months ago)
Expired
US9457036 Compositions and methods for combination antiviral therapy 13 Jan, 2024
(9 months ago)
Expired
US9744181 Compositions and methods for combination antiviral therapy 13 Jan, 2024
(9 months ago)
Expired
US6703396
(Pediatric)
Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Sep, 2021
(3 years ago)
Expired
US6642245
(Pediatric)
Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 May, 2021
(3 years ago)
Expired
US6703396 Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Mar, 2021
(3 years ago)
Expired
US6642245 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 Nov, 2020
(3 years ago)
Expired
US6639071
(Pediatric)
Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 14 Aug, 2018
(6 years ago)
Expired
US6939964
(Pediatric)
Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 20 Jul, 2018
(6 years ago)
Expired
US6639071 Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 14 Feb, 2018
(6 years ago)
Expired
US5922695
(Pediatric)
Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability 25 Jan, 2018
(6 years ago)
Expired
US5935946
(Pediatric)
Nucleotide analog composition and synthesis method 25 Jan, 2018
(6 years ago)
Expired
US5977089
(Pediatric)
Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jan, 2018
(6 years ago)
Expired
US6043230
(Pediatric)
Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jan, 2018
(6 years ago)
Expired
US6939964 Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 20 Jan, 2018
(6 years ago)
Expired
US5914331
(Pediatric)
Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 02 Jan, 2018
(6 years ago)
Expired
US5922695 Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability 25 Jul, 2017
(7 years ago)
Expired
US5935946 Nucleotide analog composition and synthesis method 25 Jul, 2017
(7 years ago)
Expired
US5977089 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jul, 2017
(7 years ago)
Expired
US6043230 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jul, 2017
(7 years ago)
Expired
US5914331 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 02 Jul, 2017
(7 years ago)
Expired
US5814639
(Pediatric)
Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds 29 Mar, 2016
(8 years ago)
Expired
US5814639 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds 29 Sep, 2015
(9 years ago)
Expired
US5663169
(Pediatric)
Benzoxazinones as inhibitors of HIV reverse transcriptase 02 Mar, 2015
(9 years ago)
Expired
US5663169 Benzoxazinones as inhibitors of HIV reverse transcriptase 02 Sep, 2014
(10 years ago)
Expired
US5519021
(Pediatric)
Benzoxazinones as inhibitors of HIV reverse transcriptase 21 Nov, 2013
(10 years ago)
Expired
US5519021 Benzoxazinones as inhibitors of HIV reverse transcriptase 21 May, 2013
(11 years ago)
Expired
US5811423 Benzoxazinones as inhibitors of HIV reverse transcriptase 07 Aug, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Atripla's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List